Company profile for Dyno Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies. Our team includes world-class molecular and synthetic biologists, pro...
Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies. Our team includes world-class molecular and synthetic biologists, protein engineers and gene therapy scientists working alongside software engineers, data scientists, and AI and machine learning experts.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
LabCentral 610 Main St. Cambridge, MA 02139
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

Vietnam Medi-Pharm Expo

Not Confirmed

envelop Contact Supplier

Vietnam Medi-Pharm Expo

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20260427312941/en/Dyno-Therapeutics-to-Present-New-Capsids-and-AI-Advancements-in-Gene-Delivery-at-the-29th-American-Society-of-Gene-Cell-Therapy-ASGCT-Annual-Meeting

BUSINESSWIRE
27 Apr 2026

https://www.businesswire.com/news/home/20260408079855/en/Dyno-Therapeutics-Announces-Capsid-License-Exercised-by-Astellas-for-Skeletal-Muscle-Targeted-Gene-Delivery-Validating-AI-Powered-Technology-for-Biological-Sequence-Design

BUSINESSWIRE
08 Apr 2026

https://www.fiercebiotech.com/biotech/astellas-pharma-and-dyno-therapeutics-unearth-15m-muscle-disorder-capsid-ongoing

FIERCE BIOTECH
08 Apr 2026

https://www.businesswire.com/news/home/20260318369291/en/Dyno-Therapeutics-Launches-Dyno-Psi-Phi-an-Agentic-AI-Suite-for-Protein-Binder-Design-at-NVIDIA-GTC-2026

BUSSINESSWIRE
18 Mar 2026

https://www.businesswire.com/news/home/20260112827255/en/Dyno-Therapeutics-Launches-Dyno-yp2-a-Top-Performing-TfR1-Mediated-AAV-Capsid-to-Further-Diversify-CNS-Delivery-Portfolio

BUSINESSWIRE
12 Jan 2026

https://www.businesswire.com/news/home/20251111892100/en/Dyno-Therapeutics-and-Trisk-Bio-Announce-Strategic-Manufacturing-Partnership-Through-Expanded-Frontiers-Program

BUSINESSWIRE
11 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty